Publication of SPiReL data and class action SPiReL data have just been published in a journal. In the population CD20+/PDL-1+, 56% of the total of patients, it gives:
ORR: 46%
DCR: 77%
mPFS: 7'1 months (Lonca -accelerated approval in April 2021- gave 4'9 months).
mOS: 17'4 months (Lonca gave 9'5 months).
In the ITT ("Intention to Treat") population, it gave 10'1 months (still better than Lonca).
They insist in the possibility of combination, given the low toxicity.
https://onlinelibrary.wiley.com/doi/10.1111/ejh.13982
Does anyone knows about class action being organized in relation to the misleading statements?